The clustered regularly interspaced short palindromic repeats (CRISPR)-Cas system is an acquired immune system of bacteria and archaea. Continued research has resulted in the identification of other Cas13 proteins.
OBJECTIVE:
This review briefly describes the discovery, classification, and application of the CRISPR-Cas13 system, including recent technological advances in addition to factors affecting system performance.
METHODS:
Cas13-based molecular therapy of human, animal, and plant transcriptomes was discussed, including regulation of gene expression to combat pathogenic RNA viruses. In addition, the latest progress, potential shortcomings, and challenges of the CRISPR-Cas system for treatment of animal and plant diseases are reviewed.
RESULTS:
The CRISPR-Cas system VI is characterized by two RNA-guided higher eukaryotes and prokaryotes nucleotide-binding domains. CRISPR RNA can cleave specific RNA through the interaction between the stem-loop rich chain of uracil residues and the Cas13a protein. The CRISPR-Cas13 system has been applied for gene editing in animal and plant cells, in addition to biological detection via accurate targeting of single-stranded RNA.
CONCLUSION:
The CRISPR-Cas13 system offers a high-throughput and convenient technology for detection of viruses and potentially the development of anti-cancer drugs in the near future.
JansenREmbdenJDGaastraW, et al. Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol.2002; 43(6): 1565-1575.
2.
BarrangouRFremauxCDeveauH, et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science.2007; 315(5819): 1709-1712.
3.
DoudnaJACharpentierE. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science.2014; 346(6213): 1258096.
4.
AbudayyehOOGootenbergJSKonermannS, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science.2016; 353(6299): aaf5573.
5.
ShmakovSAbudayyehOOMakarovaKS, et al. Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. Mol Cell.2015; 60(3): 385-397.
6.
LiuLLiXMaJ, et al. The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a. Cell.2017; 170(4): 714-726.
7.
LiuLLiXWangJ, et al. Two Distant Catalytic Sites Are Responsible for C2c2 RNase Activities. Cell.2017; 168(1-2): 121-134.
8.
SmargonAACoxDBTPyzochaNK, et al. Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase Differentially Regulated by Accessory Proteins Csx27 and Csx28. Mol Cell.2017; 65(4): 618-630.
9.
ZhangBYeWYeY, et al. Structural insights into Cas13b-guided CRISPR RNA maturation and recognition. Cell Res.2018; 28(12): 1198-1201.
10.
SlaymakerIMMesaPKellnerMJ, et al. High-Resolution Structure of Cas13b and Biochemical Characterization of RNA Targeting and Cleavage. Cell Rep.2019; 26(13): 3741-3751.
11.
KonermannSLotfyPBrideauNJ, et al. Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors. Cell.2018; 173(3): 665-676.
12.
YanWXChongSZhangH, et al. Cas13d Is a Compact RNA-Targeting Type VI CRISPR Effector Positively Modulated by a WYL-Domain-Containing Accessory Protein. Mol Cell.2018; 70(2): 327-339.
13.
ZhangCKonermannSBrideauNJ, et al. Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-Cas13d. Cell.2018; 175(1): 212-223.
14.
ZhangBYeYYeW, et al. Two HEPN domains dictate CRISPR RNA maturation and target cleavage in Cas13d. Nat Commun.2019; 10(1): 2544.
15.
XuCZhouYXiaoQ, et al. Programmable RNA editing with compact CRISPR-Cas13 systems from uncultivated microbes. Nat Methods.2021; 18(5): 499-506.
16.
KannanSAltae-TranHJinX, et al. Compact RNA editors with small Cas13 proteins. Nat Biotechnol.2022; 40(2): 194-197.
17.
MakarovaKSWolfYIIranzoJ, et al. Evolutionary classification of CRISPR-Cas systems: A burst of class 2 and derived variants. Nat Rev Microbiol.2020; 18(2): 67-83.
18.
MakarovaKSZhangFKooninEV. SnapShot: Class 1 CRISPR-Cas Systems. Cell.2017; 168(5): 946-946.
19.
MakarovaKSZhangFKooninEV. SnapShot: Class 2 CRISPR-Cas Systems. Cell.2017; 168(1-2): 328-328.
20.
WangJLiJZhaoH, et al. Structural and Mechanistic Basis of PAM-Dependent Spacer Acquisition in CRISPR-Cas Systems. Cell.2015; 163(4): 840-853.
21.
TakeuchiNWolfYIMakarovaKS, et al. Nature and intensity of selection pressure on CRISPR-associated genes. J Bacteriol.2012; 194(5): 1216-1225.
22.
AbudayyehOOGootenbergJSEssletzbichlerP, et al. RNA targeting with CRISPR-Cas13. Nature.2017; 550(7675): 280-284.
23.
CuiJTechakriengkraiNNedumpunT, et al. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci Rep.2020; 10(1): 9617.
24.
ZhaoXLiuLLangJ, et al. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Lett.2018; 431: 171-181.
25.
FreijeCAMyhrvoldCBoehmCK, et al. Programmable Inhibition and Detection of RNA Viruses Using Cas13. Mol Cell.2019; 76(5): 826-837.
26.
WangQLiuXZhouJ, et al. The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells. Adv Sci (Weinh).2019; 6(20): 1901299.
FarehMZhaoWHuW, et al. Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. Nat Commun.2021; 12(1): 4270.
29.
KushawahGHernandez-HuertasLAbugattas-Nuñez Del PradoJ, et al. CRISPR-Cas13d Induces Efficient mRNA Knockdown in Animal Embryos. Dev Cell.2020; 54(6): 805-817.
30.
HeBPengWHuangJ, et al. Modulation of metabolic functions through Cas13d-mediated gene knockdown in liver. Protein Cell.2020; 11(7): 518-524.
31.
AmanRAliZButtH, et al. RNA virus interference via CRISPR/Cas13a system in plants. Genome Biol.2018; 19(1): 1.
32.
ZhangTZhaoYYeJ, et al. Establishing CRISPR/Cas13a immune system conferring RNA virus resistance in both dicot and monocot plants. Plant Biotechnol J.2019; 17(7): 1185-1187.
33.
YuYPanZWangX, et al. Targeting of SPCSV-RNase3 via CRISPR-Cas13 confers resistance against sweet potato virus disease. Mol Plant Pathol.2022; 23(1): 104-117.
34.
AmanRMahasAButtH, et al. Engineering RNA Virus Interference via the CRISPR/Cas13 Machinery in Arabidopsis. Viruses.2018; 10(12): 732.
35.
ZhanXZhangFZhongZ, et al. Generation of virus-resistant potato plants by RNA genome targeting. Plant Biotechnol J.2019; 17(9): 1814-1822.
36.
GootenbergJSAbudayyehOOKellnerMJ, et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science.2018; 360(6387): 439-444.
37.
GootenbergJSAbudayyehOOLeeJW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science.2017; 356(6336): 438-442.
38.
AckermanCMMyhrvoldCThakkuSG, et al. Massively multiplexed nucleic acid detection with Cas13. Nature.2020; 582(7811): 277-282.
39.
AgrawalSFantonAChandrasekaranSS, et al. Rapid, point-of-care molecular diagnostics with Cas13. medRxiv. 2021.
40.
ShinodaHTaguchiYNakagawaR, et al. Amplification-free RNA detection with CRISPR-Cas13. Commun Biol.2021; 4(1): 476.
41.
RauchJNValoisESolleySC, et al. A Scalable, Easy-to-Deploy Protocol for Cas13-Based Detection of SARS-CoV-2 Genetic Material. J Clin Microbiol.2021; 59(4): e02402-02420.
42.
ThakkuSGAckermanCMMyhrvoldC, et al. Multiplexed detection of bacterial nucleic acids using Cas13 in droplet microarrays. PNAS Nexus.2022; 1(1): pgac021.
43.
IslamKUIqbalJ. An update on molecular diagnostics for COVID-19. Front Cell Infect Microbiol.2020; 10: 560616.
44.
El WahedAAPatelPMaierM, et al. Suitcase Lab for Rapid Detection of SARS-CoV-2 Based on Recombinase Polymerase Amplification Assay. Anal Chem.2021; 93(4): 2627-2634.
45.
PanZLuJWangN, et al. Development of a TaqMan-probe-based multiplex real-time PCR for the simultaneous detection of emerging and reemerging swine coronaviruses. Virulence.2020; 11(1): 707-718.
46.
AliZAmanRMahasA, et al. iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2. Virus Res.2020; 288: 198129.
47.
MyhrvoldCFreijeCAGootenbergJS, et al. Field-deployable viral diagnostics using CRISPR-Cas13. Science.2018; 360(6387): 444-448.
48.
Arizti-SanzJFreijeCAStantonAC, et al. Integrated sample inactivation, amplification, and Cas13-based detection of SARS-CoV-2. bioRxiv.2020; 11(1): 5921.
49.
Arizti-SanzJBradleyAZhangYB, et al. Equipment-free detection of SARS-CoV-2 and Variants of Concern using Cas13. medRxiv.2021; 6(8): 932-943.
50.
JoungJLadhaASaitoM, et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv. 2020.
51.
Arizti-SanzJFreijeCAStantonAC, et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. Nat Commun.2020; 11(1): 5921.
52.
BarnesKGLachenauerAENitidoA, et al. Deployable CRISPR-Cas13a diagnostic tools to detect and report Ebola and Lassa virus cases in real-time. Nat Commun.2020; 11(1): 4131.
53.
TianTShuBJiangY, et al. An Ultralocalized Cas13a Assay Enables Universal and Nucleic Acid Amplification-Free Single-Molecule RNA Diagnostics. ACS Nano.2021; 15(1): 1167-1178.
54.
López-VallsMEscalona-NogueroCRodríguez-DíazC, et al. CASCADE: Naked eye-detection of SARS-CoV-2 using Cas13a and gold nanoparticles. Anal Chim Acta.2022; 1205: 339749.
55.
RenJZhaoY. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9. Protein Cell.2017; 8(9): 634-643.
56.
CyranoskiD. Chinese scientists to pioneer first human CRISPR trial. Nature.2016; 535(7613): 476-477.
57.
CyranoskiD. CRISPR gene-editing tested in a person for the first time. Nature.2016; 539(7630): 479.
58.
LuYXueJDengT, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nature Medicine.2020; 26(5): 1-9.
59.
WangEZhouHNadorpB, et al. Surface antigen-guided CRISPR screens identify regulators of myeloid leukemia differentiation. Cell Stem Cell.2021; 28(4): 718-731 e6.
60.
ZafraMPSchatoffEMKattiA, et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat Biotechnol.2018; 36(9): 888-893.
61.
FengYSassiSShenJK, et al. Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. J Orthop Res.2015; 33(2): 199-207.
62.
LiuTYanZLiuY, et al. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells. Cell Physiol Biochem.2018; 46(3): 1218-1230.
63.
LiuTLiZZhangQ, et al. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance. Oncotarget.2016; 7(50): 83502-83513.
64.
XuXJXinSJMaoHY, et al. SHOX CNE9/10 Knockout in U2OS Osteosarcoma Cells and Its Effects on Cell Growth and Apoptosis. Med Sci Monit.2020; 26: e921233.
65.
WuJZhiLDaiX, et al. Decreased RECQL5 correlated with disease progression of osteosarcoma. Biochem Biophys Res Commun.2015; 467(4): 617-622.
66.
MarkoTAShamsanGAEdwardsEN, et al. Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma. Sci Rep.2016; 6: 39059.
67.
BördingTAbdoANMaierB, et al. Generation of Human CRY1 and CRY2 Knockout Cells Using Duplex CRISPR/Cas9 Technology. Front Physiol.2019; 10: 577.
68.
GötteBPanasMDHellströmK, et al. Separate domains of G3BP promote efficient clustering of alphavirus replication complexes and recruitment of the translation initiation machinery. PLoS Pathog.2019; 15(6): e1007842.
69.
SotiriouSKKamileriILugliN, et al. Mammalian RAD52 functions in break-induced replication repair of collapsed DNA replication forks. Mol Cell.2016; 64(6): 1127-1134.
70.
TaniharaFHirataMNguyenNT, et al. Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation. PLoS One.2018; 13(10): e0206360.
71.
MizoshiriNShiraiTTerauchiR, et al. The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma. Cell Oncol (Dordr).2019; 42(6): 861-871.
72.
GollavilliPNPawarAWilder-RomansK, et al. EWS/ETS-driven ewing sarcoma requires BET bromodomain proteins. Cancer Res.2018; 78(16): 4760-4773.
73.
MaruyamaRYokotaT. Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping. Methods Mol Biol.2018; 1828: 165-171.
74.
De LunaNSuarez-CalvetXGaricanoM, et al. Effect of MAPK inhibition on the differentiation of a rhabdomyosarcoma cell line combined with CRISPR/Cas9 technology: An in vitro model of human muscle diseases. J Neuropathol Exp Neurol.2018; 77(10): 964-972.
75.
GrissaIVergnaudGPourcelC. CRISPRFinder: A web tool to identify clustered regularly interspaced short palindromic repeats. Nucleic Acids Res.2007; 35(Web Server issue): W52-W57.
76.
GrissaIVergnaudGPourcelC. The CRISPRdb database and tools to display CRISPRs and to generate dictionaries of spacers and repeats. BMC Bioinformatics.2007; 8: 172.
77.
HwangWYFuYReyonD, et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol.2013; 31(3): 227-229.
78.
DoenchJGHartenianEGrahamDB, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol.2014; 32(12): 1262-1267.
79.
DoenchJGFusiNSullenderM, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol.2016; 34(2): 184-191.
80.
WongNLiuWWangX. WU-CRISPR: Characteristics of functional guide RNAs for the CRISPR/Cas9 system. Genome Biol.2015; 16: 218.
81.
KaurKTandonHGuptaAK, et al. CrisprGE: A central hub of CRISPR/Cas-based genome editing. Database (Oxford).2015; 2015: bav055.
82.
DiazAAQinHRamalho-SantosM, et al. HiTSelect: A comprehensive tool for high-complexity-pooled screen analysis. Nucleic Acids Res.2015; 43(3): e16.
83.
LiWXuHXiaoT, et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. Genome Biol.2014; 15(12): 554.
84.
LiWKösterJXuH, et al. Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR. Genome Biol.2015; 16: 281.
85.
YuJSilvaJCalifanoA. ScreenBEAM: A novel meta-analysis algorithm for functional genomics screens via Bayesian hierarchical modeling. Bioinformatics.2016; 32(2): 260-267.
86.
JiangPWangHLiW, et al. Network analysis of gene essentiality in functional genomics experiments. Genome Biol.2015; 16: 239.
87.
MerkleTMerzSReautschnigP, et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat Biotechnol.2019; 37(2): 133-138.
88.
YiZQuLTangH, et al. Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo. Nat Biotechnol.2022; 40(6): 946-955.
89.
AbudayyehOOGootenbergJSFranklinB, et al. A cytosine deaminase for programmable single-base RNA editing. Science.2019; 365(6451): 382-386.
90.
AiYLiangDWiluszJE. CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells. Nucleic Acids Res.2022; 50(11): e65.
91.
TongHHuangJXiaoQ, et al. High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects. Nat Biotechnol.2023; 41(1): 108-119.
92.
WuQWKapfhammerJP. The Bacterial Enzyme Cas13 Interferes with Neurite Outgrowth from Cultured Cortical Neurons. Toxins (Basel).2021; 13(4): 262.
93.
ÖzcanAKrajeskiRIoannidiE, et al. Programmable RNA targeting with the single-protein CRISPR effector Cas7-11. Nature.2021; 597(7878): 720-725.
94.
BurrisBJDMolina VargasAMParkBJ, et al. Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13. Methods.2022; 206: 58-68.
95.
ZhangYRestallJCrispP, et al. Current status and prospects of plant genome editing in Australia. In Vitro Cell Dev Biol Plant.2021; 57(4): 574-583.
